We performed antinociceptive testing on swine receiving buprenorphine. Intr
avenous access was achieved, and animals were allowed to recover for 24 h.
Baseline skin-twitch latency to a focused light source was determined for e
ach animal. Animals received intravenous (i.v.) buprenorphine at 0.08 (n =
1), 0.16 (n = 1), 0.005 (n = 5), 0.01 (n = 5), or 0.02 mg/kg (n = 6). Skin-
twitch latency was determined 15, 30, 60, 120, 180, 240, 300, 360, 420, 480
, 540, and 600 min after buprenorphine administration. Analgesic activity a
s measured by a significant increase in latency time over baseline values o
ccurred at all time points except 480 min in animals that received 0.02 mg/
kg buprenorphine i.v. Analgesic activity to 420 min was demonstrated in ani
mals that received 0.01 mg/kg buprenorphine i.v. Analgesic activity was not
demonstrated at any time paint in animals that received 0.005 mg/kg bupren
orphine i.v. A retrospective analysis of postoperative care records was per
formed to determine whether 0.01 mg/kg buprenorphine i.v. or intramuscularl
y (i.m.) postoperatively to swine provided clinically relevant analgesia. R
ecords of swine receiving buprenorphine from 1997 to 2000 were reviewed for
indications of treatment failure, such as pain or a change in analgesic re
gimen from that used routinely. Treatment Failure occurred in 18 of 416 (4.
3%) cases treated with buprenorphine. This failure occurred in 17% of cases
with problems categorized as inflammatory in nature and in 15.5% of those
with systemic problems or organ failure. We concluded that antinociceptive
testing predicted that buprenorphine administered at 0.01 mg/kg i.v. in swi
ne likely would provide analgesic efficacy for 6 h and when administered at
0.02 mg/kg i.v. likely would provide 10 h analgesia. Clinical signs of pai
n in animals recovering from surgery were not observed in the majority of c
ases when buprenorphine was administered twice or thrice daily at 0.01 mg/k
g i.m. or i.v. However, buprenorphine was less effective at treating signs
of pain associated with inflammation, organ failure, or systemic disease th
an at ameliorating pain associated,vith surgical incisions and orthopedic,
dental, and ophthalmic procedures.